Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
NICE backs Novartis' Adakveo via special channel despite 'high uncertainty' about cost, long-term efficacy | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
ASCO: Positive trial shows Novartis' Kymriah poised to play catch-up in CAR- T rivalry with Gilead's Yescarta | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says | Fierce Pharma
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada | Fierce Pharma
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
The Process of CAR-T Cell Therapy | Novartis
ASCO: Gilead's Kite soars over Novartis' CAR-T turf with Tecartus win in type of leukemia | Fierce Pharma
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
Non-viral precision T cell receptor replacement for personalized cell therapy | Nature
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule :: Pink Sheet
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
